Coeptis Therapeutics Holdings, Inc. acquires Z Squared Inc. (2025)

Deal facts

Buyer: Coeptis Therapeutics Holdings, Inc.
Target: Z Squared Inc.
Deal value: Not disclosed
Announced: 25 April 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

24 Apr 2026CompletedClosed
Coeptis Therapeutics Holdings, Inc. completes acquisition of Z Squared Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets Item 5.01 Changes in Control of the Registrant Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01 Financial Statements and Exhibits ii TA
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Z Squared Inc by Coeptis Therapeutics Holdings, Inc. This strategic move within the US healthcare sector highlights a growing preference for all-share consideration in life sciences transactions. The deal, announced on 25 April 2025 and now closed, demonstrates that buyers are willing to use their own equity to secure critical assets rather than depleting cash reserves. For the SME founder in the biotech space, this structure often aligns interests more closely than a cash exit, as both parties remain exposed to the combined entity future performance.

The choice of shares as the sole consideration type suggests the buyer views Z Squared as a long-term integration play rather than a quick flip. In the US market, this mechanism can defer tax liabilities for the target shareholders, but it also introduces immediate concentration risk. You must understand that your wealth becomes tied to the buyer's share price volatility post-close. Unlike a cash deal where value is fixed at signing, an all-share transaction means your final exit value fluctuates with market sentiment until the lock-up period expires. This is a standard commercial mechanic in strategic acquisitions, yet it requires founders to assess the buyer's balance sheet strength and liquidity before agreeing to the terms.

Regulatory clearance in the healthcare sector is rarely straightforward, even for domestic US deals. While the specific antitrust thresholds are not detailed in the announcement, any merger involving therapeutic assets typically triggers scrutiny from the Federal Trade Commission regarding competition and market concentration. The fact that this transaction has reached completion status implies that all necessary regulatory hurdles were cleared without material delay. This smooth path is encouraging for other founders navigating similar paths, but it should not breed complacency. You must still prepare for rigorous due diligence on your intellectual property and clinical data, as these remain the primary triggers for regulatory intervention in this sector.

We believe the immediate lesson for the founder is to model the post-deal share structure before signing the term sheet. Do not accept a share-only offer without running a sensitivity analysis on how a 20 per cent drop in the buyer's stock price would affect your total consideration. This week, request a copy of the buyer's most recent quarterly report and calculate your hypothetical exit value under three different share price scenarios. This simple exercise will tell you if the deal offers genuine upside or merely shifts your risk profile from a single asset to a broader market exposure.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from Coeptis Therapeutics Holdings, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history